Figure 6 from Schlafen 12 Modulation and Targeting in Acute Myeloid Leukemia
Year: 2025
Type: other
Abstract: Antileukemic activity of BAY 2666605 in vivo. A, Schematic representation of the experimental approach for the treatment regimen used for the xenograft AML mouse model. B, Tumor volumes (means ± SEM) are shown for mice treated with either vehicle control (5% ethanol with 95% polyethylene glycol-400) or BAY 2666605 (5 mg/kg; n = 10 per group). Pink bars indicate treatment window. Tumor growth from the start of treatment (day 13) until the end of treatment (day 24) was analyzed using a mixed-effects linear regression model. Tumor volume was log-transformed to satisfy the normality assumption. Treatment group, time, and their interaction were included as fixed effects and mice as a random effect. The interaction was statistically significant (P < 0.0001). The P values comparing treatments at each time point were adjusted for multiple comparisons using the Holm–Šídák method; *, P ≤ 0.05. Arrowheads indicate when mice were euthanized because of meeting study endpoints after tumor volume measurement. C, Kaplan–Meier survival analysis for mice treated with BAY 2666605 vs. vehicle control. Mice were compassionately euthanized once tumor volume was ≥2,000 mm3 or weight loss was greater than 20%; ***, P = 0.0004 using a Mantel–Cox (log-rank) test. D, Table summarizing estimated median survival (in days) of mice from each treatment group. BAY, BAY 2666605; SQ, subcutaneous. [A, Created in BioRender. Guillen Magana, J. (2025) https://BioRender.com/yw4tt0f.]
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4416300044
Cites:
Cited by:
Related to: